Status:
RECRUITING
SGLT2 Inhibitors in Geographic Atrophy
Lead Sponsor:
Washington University School of Medicine
Conditions:
Retinal Degeneration
Retinal Diseases
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive reti...
Detailed Description
This is a Phase II, prospective, single-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral dapagliflozin in subjects with geographic at...
Eligibility Criteria
Inclusion
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
- Participant is male or, if female, participant is surgically sterilized or amenorrheic for at least one year
- ≥50 years old
- Evidence of dry advanced AMD with the presence of non-foveal Geographic Atrophy (GA)
- The geographic atrophy must not involve the center point of the fovea.
- Total area of geographic atrophy must be between 2.5 mm2 and 17.5 mm2 (1 - 4 disc areas, respectively).
- If the geographic atrophy consists of multiple lesions, at least one lesion must have an area of ≥1.25 mm² (equivalent to 0.5 disc areas).
- BCVA between 20/25 and 20/320
- Must be treatment-naïve for AMD, except for oral supplements
Exclusion
- Prior investigational drug use within 60 days
- Use of other SGLT2 inhibitors
- History of symptomatic hypotension or symptomatic hypotension (symptoms of hypotension + SBP \< 90mmHg) at baseline
- Type I and Type II Diabetes Mellitus
- End stage renal disease or estimated glomerular filtration rate less than 25 mL/min/1.73 m2 per MDRD calculation
- History of heart failure
- History of a serious hypersensitivity reaction to dapagliflozin or any of the excipients in FARXIGA
- Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures
- Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins or mineral
- Any intraocular surgery or thermal laser within 3 months of date of randomization
- Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks
- Any prior thermal laser in the macular region, regardless of indication (self-report)
- Any evidence of choroidal neovascularization in study eye
- Enrollment in another interventional trial during the trial period
Key Trial Info
Start Date :
December 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT07174687
Start Date
December 2 2025
End Date
June 1 2028
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University
St Louis, Missouri, United States, 63110